

EndoPredict®

Breast Cancer Prognostic Test

Patient guide
to the EndoPredict
Breast Cancer
Prognostic Test



A COMMON DIAGNOSIS

Breast cancer is recognized as one of the most important medical problems facing women. Nearly 2.3 million women were diagnosed with breast cancer worldwide in 2020.¹ About 1 in 8 women receive a diagnosis of breast cancer in their lifetime.²

But not all breast cancers are the same and so they are treated in different ways. After initial surgery and sometimes radiation, some women with early-stage, estrogen receptor positive (ER+) and HER2 receptor negative (HER2-) breast cancer can be safely treated with just hormone therapy for 5 years. Meanwhile, others may benefit from also having chemotherapy and/or prolonged hormone therapy.

Confused about which breast cancer treatment is right for you?



A diagnosis of breast cancer can be a stressful time. You may be feeling overwhelmed with decisions and looking for answers.

The EndoPredict Breast Cancer Prognostic Test provides personalized genomic information about how your breast cancer is behaving, giving you and your physician confidence to choose the treatment plan that is right for you.

How EndoPredict benefits you

EndoPredict is a genomic test that illuminates your risk of your breast cancer returning (known as breast cancer recurrence) both in the near future and long-term, to help guide important treatment decisions for your own cancer journey. This makes it possible to personalize treatment to you.



EndoPredict provides answers to pressing questions




- What is the risk of my cancer spreading outside of the breast; short- and long-term?
- Am I a candidate for 5 years hormone therapy only after surgery?
- Would I benefit from chemotherapy?


WHAT IS ENDOPREDICT?

EndoPredict is a second generation gene expression test - the newest type of test for predicting breast cancer recurrence. It is for post- and premenopausal women with early (non-metastatic) ER+, HER2- breast cancer with or without affected lymph nodes.

EndoPredict accurately measures the activity of specific genes that influence tumor growth, resulting in a 12-Genes Molecular Score. This allows conclusions about the likely outcome of the cancer (prognosis). Higher scores are associated with a higher risk.



EndoPredict combines this genomic fingerprint of your individual breast cancer with measurements, like tumor size and the number of positive lymph nodes. This provides your individual EPclin Risk Score, which allows a more accurate assessment of your early and late (up to 15 years) recurrence risk.



CLEAR RESULTS TAILORED TO YOU

What do your EndoPredict test results mean?

You will receive a number, called your EPclin Risk Score, which is reported on a scale that reflects the likelihood of your breast cancer returning in the future. This defines your individual EPclin Risk Class, which may be high-risk or low-risk. Values below 3.33 are considered low-risk. The value of 3.33 is associated with a 10% chance of breast cancer recurrence within 10 years and serves as a cut-off.

Results

EPclin
Risk Score
2.0

EPclin
Risk Class
LOW

If you are EPclin low-risk, then your cancer is unlikely to return and you may benefit from 5 years of hormone therapy alone.

Results

EPclin
Risk Score
3.8

EPclin
Risk Class
HIGH

If you are EPclin high-risk, then chemotherapy and/or extended hormone treatment beyond 5 years can help you to reduce the risk of your cancer returning.

Regardless of your result, treatment is personalized to you





EndoPredict stops you from being part of a group and allows you to be seen as a person rather than a category

ENDOPREDICT IS PERSONALIZING BREAST CANCER TREATMENT

Is chemotherapy right for you?

EndoPredict shows your individual risk of your breast cancer returning in the next 10 years if you were treated by hormone therapy alone.³ It also estimates how much chemotherapy is likely to reduce the risk of your breast cancer returning.⁴ As tumors treated with chemotherapy could also return, the benefits of chemotherapy may not outweigh the potential side-effects for you.

Low-risk example	Initial treatment planning	Likelihood of distant recurrence within years 0-10 For patients treated with 5 years of endocrine therapy alone	3%
		Absolute chemotherapy benefit at 10 years	0%
High-risk example	Initial treatment planning	Likelihood of distant recurrence within years 0-10 For patients treated with 5 years of endocrine therapy alone	16%
		Absolute chemotherapy benefit at 10 years	6%

This information will help you and your doctor to make a safe, informed decision about your initial treatment.

Should extended hormone therapy be considered?

EndoPredict shows your risk of your breast cancer returning in the 10 years after you received 5 years of hormone therapy.⁵ This can help you and your doctor to decide if 5 years of hormone therapy is enough or if extended hormone therapy should be considered.

Low-risk example	Long-term treatment planning	Likelihood of late distant recurrence within years 5-15 For patients with no recurrence after 5 years of endocrine therapy alone	2%
High-risk example	Long-term treatment planning	Likelihood of late distant recurrence within years 5-15 For patients with no recurrence after 5 years of endocrine therapy alone	12%

This information is provided before you start treatment with drugs, so you can make treatment decisions for the present and future.

So many women are being overtreated with chemotherapy, the EndoPredict test allows each patient's needs to be considered in order to provide the necessary treatment



HOW ENDOPREDICT IS PERFORMED



Better answers start with you

EndoPredict is performed on your initial biopsy or surgery tissue. To get started, first talk to your doctor to see if prognostic testing of your tumor might be appropriate.



Doctor orders the EndoPredict test

The test can be requested from one of the performing pathology labs in your country. The pathologist requires a sample from your existing breast cancer tissue. No additional blood or biopsy samples are required.



Your genes are analyzed in the pathology lab

Using the latest gene expression technology based on tumor RNA, in combination with clinical-pathological factors, EndoPredict measures how fast your cancer is growing.



Test results available in around 1 week

Once the results are available, they are sent to your doctor's office. Your doctor will then help you understand how your cancer is behaving, giving you the confidence to take the next step.

TALKING TO YOUR DOCTOR ABOUT THE ENDOPREDICT TEST



Be prepared

Do your research on possible breast cancer treatments, side-effects, and biomarker tests - like EndoPredict. Come prepared to your cancer consultation with any information the doctor or staff may need to see. Make sure to bring along the EndoPredict patient guide.



Be open and confident

Remember that your doctor is on your side. You both want what's best for you and helping successfully manage your cancer is everyone's top priority. So just be open and honest about potential treatments or possible side-effects.



Bring your support team

The support of family members or close friends can help facilitate the conversation with your doctor and they can help act as a co-advocate for your care at your next appointment.

YOU CAN TRUST ENDOPREDICT TO GUIDE THE RIGHT DECISION FOR YOUR BREAST CANCER

WANT TO KNOW MORE?

Why choose EndoPredict?



Widely used in patients across more than 25 countries



Fast results for early treatment planning



Your individual risk for personalized treatment



Recommended by global cancer experts and guidelines

About Eurobio Scientific

Eurobio Scientific is a global company with a mission to improve patients' quality of life through specialty diagnostics. Our vision is to become a leading global specialty diagnostics company by offering highly innovative solutions to healthcare professionals to serve this purpose.

With more than 370 employees worldwide, Eurobio Scientific is dedicated to providing local support through our four manufacturing centers, three research centers, and local offices in France, The Netherlands, Germany, Italy, Switzerland, the UK, and the USA.

Our expert R&D team gather years of experience in developing advanced molecular diagnostic tests in the fields of transplant, oncology, and infectious diseases.

How is EndoPredict different to other breast cancer prognostic tests?

EndoPredict is different because in direct comparison it is more accurate than first generation tests.^{6,7} EndoPredict is the only test that can predict breast cancer recurrence risk out to 15 years.⁵ Unlike other tests, it provides an estimate of individual chemotherapy benefit.⁴ The risk estimate can guide treatment decisions now and in the future for pre- and postmenopausal patients.

Is EndoPredict a genetic test like BRCA testing?


No, EndoPredict is a genomic test which analyzes your cancer for activity of certain genes that indicate how likely it is to grow and spread. This helps you and your doctor to make safe treatment decisions. BRCA testing is a genetic test that indicates whether you have a mutation in a gene linked to a higher risk of developing breast cancer in your life.

Can EndoPredict be used when lymph nodes are involved?

Yes, EndoPredict can be used when positive lymph nodes have been found. EndoPredict gives the most accurate prognosis for node positive patients,⁶ guiding both early and long-term treatment planning.

Where can you find out more information?

You can find out more on EndoPredict at our website: www.eurobio-scientific.de



References:

1. International Agency for Research On Cancer, WHO, GLOBOCAN 2020. Breast fact sheet, 2020. Accessed on August 09, 2022. <https://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf>. 2022.
2. Surveillance Research Program, National Cancer Institute. SEER Explorer. Breast cancer- Comparison of cancer risk, 2017-2019, by risk type and risk interval, female, all races, risk from age 0. Accessed on August 09, 2022. <https://seer.cancer.gov/explorer/>, 2022.
3. Filipits, Martin et al. "A New Molecular Predictor Of Distant Recurrence In ER-Positive, HER2-Negative Breast Cancer Adds Independent Information To Conventional Clinical Risk Factors". *Clinical Cancer Research*, vol 17, no. 18, 2011, pp. 6012-6020.
4. Sestak, Ivana et al. "Prediction Of Chemotherapy Benefit By EndoPredict In Patients With Breast Cancer Who Received Adjuvant Endocrine Therapy Plus Chemotherapy Or Endocrine Therapy Alone". *Breast Cancer Research And Treatment*, vol 176, no. 2, 2019, pp. 377-386.
5. Filipits, Martin et al. "Prediction Of Distant Recurrence Using EndoPredict Among Women With ER+, HER2- Node-Positive And Node-Negative Breast Cancer Treated With Endocrine Therapy Only". *Clinical Cancer Research*, vol 25, no. 13, 2019, pp. 3865-3872.
6. Sestak, Ivana et al. "Comparison Of The Performance Of 6 Prognostic Signatures For Estrogen Receptor-Positive Breast Cancer". *JAMA Oncology*, vol 4, no. 4, 2018, pp. 545-553.
7. Buus, Richard et al. "Comparison Of EndoPredict And EPclin With Oncotype DX Recurrence Score For Prediction Of Risk Of Distant Recurrence After Endocrine Therapy". *Journal Of The National Cancer Institute*, vol 108, no. 11, 2016, p. djw149.

eurobio
SCIENTIFIC

Eurobio Scientific GmbH
Nattermannallee 1, Building S19
50829 Köln
Germany

info-INT@eurobio-scientific.de
www.eurobio-scientific.de



Eurobio Scientific, the Eurobio Scientific logo, EndoPredict and the EndoPredict logo are either trademarks or registered trademarks of Eurobio Scientific. ©2024 Eurobio Scientific GmbH

ENDO_PT_BRO_GUIDE_08_24_EN

